Review



b7h3  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    R&D Systems b7h3
    Figure 1. Schematic representation of our hybrid-SELEX method for selection of <t>B7H3-specific</t> ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.
    B7h3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/Recombinant+Mouse+B7-H3+Protein/pm38866941-139-7-8
    Average 92 stars, based on 8 article reviews
    b7h3 - by Bioz Stars, 2026-10
    92/100 stars

    Images

    1) Product Images from "Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays."

    Article Title: Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays.

    Journal: Scientific reports

    doi: 10.1038/s41598-024-64559-7

    Figure 1. Schematic representation of our hybrid-SELEX method for selection of B7H3-specific ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.
    Figure Legend Snippet: Figure 1. Schematic representation of our hybrid-SELEX method for selection of B7H3-specific ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.

    Techniques Used: Selection, Control, Recombinant, Dot Blot, Incubation, Magnetic Beads

    Figure 2. Monitoring the enrichment of the DNA libraries during hybrid-SELEX by flow cytometry and dot- blot. (a) Fluorescence intensities of target cells (Weri-RB1) incubated with FITC-labelled ssDNA pools from the initial library to the ninth-selection round. (b) Fluorescence intensities of negative control cells (Mio-M1) incubated with FITC-labelled ssDNA pools from the initial library to the ninth-selection round. (c) Represented is the dot-blot assay showing the fluorescence intensities of ssDNA pools from the initial library to the ninth- selection round, bound to the recombinant B7H3 protein.
    Figure Legend Snippet: Figure 2. Monitoring the enrichment of the DNA libraries during hybrid-SELEX by flow cytometry and dot- blot. (a) Fluorescence intensities of target cells (Weri-RB1) incubated with FITC-labelled ssDNA pools from the initial library to the ninth-selection round. (b) Fluorescence intensities of negative control cells (Mio-M1) incubated with FITC-labelled ssDNA pools from the initial library to the ninth-selection round. (c) Represented is the dot-blot assay showing the fluorescence intensities of ssDNA pools from the initial library to the ninth- selection round, bound to the recombinant B7H3 protein.

    Techniques Used: Flow Cytometry, Dot Blot, Fluorescence, Incubation, Selection, Negative Control, Recombinant

    Figure 3. Binding ability, secondary structures and dissociation constants of selected B7H3 aptamers. (a) Binding affinity of FITC-labelled aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 to Weri-RB1 cells assessed by flow cytometry. (b) Binding ability of FITC-labelled aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 to Mio-M1 cells assessed by flow cytometry. (c–g) Predicted secondary structures for five aptamer candidates, VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 selected for further. The presented predicted secondary structures were the ones with lowest ΔG. Constant sequence regions are highlighted in black, and green represents the random regions. (h–l) Binding curve of aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 with Weri-RB1 and Mio-M1 cells assessed by flow cytometry and recombinant B7H3 protein by dot-blot. Equilibrium dissociation constants (Kd) (nM) were calculated using GraphPad Prism 7, under the non-linear fit model, one-site non-competitive binding to fluorescent population ratio at used aptamer concentrations.
    Figure Legend Snippet: Figure 3. Binding ability, secondary structures and dissociation constants of selected B7H3 aptamers. (a) Binding affinity of FITC-labelled aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 to Weri-RB1 cells assessed by flow cytometry. (b) Binding ability of FITC-labelled aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 to Mio-M1 cells assessed by flow cytometry. (c–g) Predicted secondary structures for five aptamer candidates, VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 selected for further. The presented predicted secondary structures were the ones with lowest ΔG. Constant sequence regions are highlighted in black, and green represents the random regions. (h–l) Binding curve of aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 with Weri-RB1 and Mio-M1 cells assessed by flow cytometry and recombinant B7H3 protein by dot-blot. Equilibrium dissociation constants (Kd) (nM) were calculated using GraphPad Prism 7, under the non-linear fit model, one-site non-competitive binding to fluorescent population ratio at used aptamer concentrations.

    Techniques Used: Binding Assay, Flow Cytometry, Sequencing, Recombinant, Dot Blot

    Figure 4. Affinity of B7H3 aptamers by Dot-blot and western blot analysis. (a) Dot-blot assay with (i–v) FITC labelled and (vi–x) biotin labelled aptamers to demonstrate the capability of the B7H3 aptamers to recognize their target immobilized on PVDF membranes; (i) & (vi)—VRF-HS_B7H3-01, (ii) & (vii)—VRF-HS_B7H3-02, (iii) & (viii)—VRF-HS_B7H3-03, (iv) & (viii)—VRF-HS_B7H3-04 and (v) & (x)—VRF-HS_B7H3-05; 1— B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate, 4—BSA, 5—Weri-RB1 secretome and 6—Secondary control. (b) Sandwich dot blot assay with (i–iii) biotin labelled and (ii–iv) FITC labelled aptamers to demonstrate the capability of aptamers to recognize different epitopes of their target immobilized on nitrocellulose membranes. (i) & (ii)—unlabelled VRF-HS_B7H3-01 is used as capture and FITC or biotin labelled VRF-HS_B7H3-03 is used for detection, (iii) & (iv) unlabelled VRF-HS_B7H3-03 is used as capture and FITC or biotin labelled VRF-HS_B7H3-01 is used for detection; 1—B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate, 4—Weri-RB1 secretome and 5—BSA. (c) Comparison of the specificity of B7H3 antibody to VRF-HS_B7H3-03 aptamer in a protein blot analysis (cropped image). Lane 1—B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate and 4—Mio-M1 protein lysate; (i) Probed with anti-B7H3 Rabbit monoclonal antibody, (ii) Probed with biotinylated VRF-HS_B7H3-03 aptamer and (iii) & (iv) Probed with GAPDH mouse monoclonal antibody. Results of an aptamer blot from a nonreducing SDS polyacrylamide gel in which B7H3 was clearly detected near 90 kDa similar to antibody. However, the recombinant protein manufacturer of the B7H3 (R&D systems) reported a molecular weight of 38–48 kDa for its product which is consistent with the strongly detected band’s weight (Full raw blot included in Supplementary data Fig. S5).
    Figure Legend Snippet: Figure 4. Affinity of B7H3 aptamers by Dot-blot and western blot analysis. (a) Dot-blot assay with (i–v) FITC labelled and (vi–x) biotin labelled aptamers to demonstrate the capability of the B7H3 aptamers to recognize their target immobilized on PVDF membranes; (i) & (vi)—VRF-HS_B7H3-01, (ii) & (vii)—VRF-HS_B7H3-02, (iii) & (viii)—VRF-HS_B7H3-03, (iv) & (viii)—VRF-HS_B7H3-04 and (v) & (x)—VRF-HS_B7H3-05; 1— B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate, 4—BSA, 5—Weri-RB1 secretome and 6—Secondary control. (b) Sandwich dot blot assay with (i–iii) biotin labelled and (ii–iv) FITC labelled aptamers to demonstrate the capability of aptamers to recognize different epitopes of their target immobilized on nitrocellulose membranes. (i) & (ii)—unlabelled VRF-HS_B7H3-01 is used as capture and FITC or biotin labelled VRF-HS_B7H3-03 is used for detection, (iii) & (iv) unlabelled VRF-HS_B7H3-03 is used as capture and FITC or biotin labelled VRF-HS_B7H3-01 is used for detection; 1—B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate, 4—Weri-RB1 secretome and 5—BSA. (c) Comparison of the specificity of B7H3 antibody to VRF-HS_B7H3-03 aptamer in a protein blot analysis (cropped image). Lane 1—B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate and 4—Mio-M1 protein lysate; (i) Probed with anti-B7H3 Rabbit monoclonal antibody, (ii) Probed with biotinylated VRF-HS_B7H3-03 aptamer and (iii) & (iv) Probed with GAPDH mouse monoclonal antibody. Results of an aptamer blot from a nonreducing SDS polyacrylamide gel in which B7H3 was clearly detected near 90 kDa similar to antibody. However, the recombinant protein manufacturer of the B7H3 (R&D systems) reported a molecular weight of 38–48 kDa for its product which is consistent with the strongly detected band’s weight (Full raw blot included in Supplementary data Fig. S5).

    Techniques Used: Dot Blot, Western Blot, Recombinant, Control, Comparison, Molecular Weight

    Figure 5. Immunohistochemistry of B7H3 antibody and VRF-HS_B7H3-03 to RB tumour sections and retina. (a,d) H and E staining, (b,e) IHC with B7H3 antibody, and (c,f) IHC with biotin-labelled VRF-HS_B7H3-03 of primary retinoblastoma tumour and retina respectively.
    Figure Legend Snippet: Figure 5. Immunohistochemistry of B7H3 antibody and VRF-HS_B7H3-03 to RB tumour sections and retina. (a,d) H and E staining, (b,e) IHC with B7H3 antibody, and (c,f) IHC with biotin-labelled VRF-HS_B7H3-03 of primary retinoblastoma tumour and retina respectively.

    Techniques Used: Immunohistochemistry, Staining

    Related Articles

    Recombinant:

    Article Title: B7-H3 participates in the development of Asthma by augmentation of the inflammatory response independent of TLR2 pathway
    Article Snippet: .. The recombinant mouse B7-H3 was purchased from R&D Systems, Minneapolis, America. ..

    Article Title: Effects of B7-H3 on the inflammatory response and expression of MMP-9 in mice with pneumococcal meningitis.
    Article Snippet: B7-H3, a new member of the B7 superfamily, plays a key role in the regulation of T cell-mediated immune responses.. Our previous work showed that B7-H3 strongly augmented both LPSand bacterial lipoprotein-induced NFκB activation and inflammatory response, and soluble B7H3 was elevated in CSF and plasma of patients with bacterial meningitis.. MMP-9 has been implicated in blood–brain barrier disruption, inflammation, and vasculitis during the pathogenesis of bacterial meningitis.

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Grouping and evaluation of clinical disease status Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..

    Article Title: Activation of the TLR2-mediated downstream signaling pathways NF-κB and MAPK is responsible for B7-H3-augmented inflammatory response during S. pneumoniae infection.
    Article Snippet: It has been reported that B7-H3, a costimulatory protein, participates in the development and progression of experimental pneumococcal meningitis by amplifying the TLR2-mediated inflammatory response.. This study attempted to clarify the pathway(s) of TLR2 signaling involved in B7-H3-augmented inflammatory response during S. pneumoniae infection.. Murine microglial cell line N9 cells and primary murine microglial cells were infected with S. pneumoniae alone or in combination with B7-H3.

    Article Title: B7-H3 promoted proliferation of mouse spermatogonial stem cells via the PI3K signaling pathway
    Article Snippet: Anti-PI3K antibody was obtained from Cell Signaling Technology (Boston, USA). .. Recombinant mouse B7-H3 was purchased from R&D Systems (Minneapolis, USA). .. Anti-phospho-PI3K antibody, anti-phospho-ERK1/2 antibody, anti-phospho-JNK1/2/3 antibody, anti-C-kit antibody, anti-Oct-4 antibody, FITC-conjugated anti-B7-H3 antibody, PE-conjugated goat anti-rat IgG, BRDU, anti-BrdU antibody and Alexa Fluor 488- conjugated goat anti-rat IgG were obtained from Abcam (Cambridge, USA).

    Article Title: B7-H3 Augments Inflammatory Responses and Exacerbates Brain Damage via Amplifying NF-κB p65 and MAPK p38 Activation during Experimental Pneumococcal Meningitis
    Article Snippet: .. Recombinant mouse B7-H3 was purchased from R&D Systems (Minneapolis, MN, USA). .. Antibodies (Abs) that recognize TLR2, MyD88, and IRAK-1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Abcam (Cambridge, MA, USA), respectively.

    Mouse Assay:

    Article Title: Effects of B7-H3 on the inflammatory response and expression of MMP-9 in mice with pneumococcal meningitis.
    Article Snippet: B7-H3, a new member of the B7 superfamily, plays a key role in the regulation of T cell-mediated immune responses.. Our previous work showed that B7-H3 strongly augmented both LPSand bacterial lipoprotein-induced NFκB activation and inflammatory response, and soluble B7H3 was elevated in CSF and plasma of patients with bacterial meningitis.. MMP-9 has been implicated in blood–brain barrier disruption, inflammation, and vasculitis during the pathogenesis of bacterial meningitis.

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Grouping and evaluation of clinical disease status Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..

    Injection:

    Article Title: Effects of B7-H3 on the inflammatory response and expression of MMP-9 in mice with pneumococcal meningitis.
    Article Snippet: B7-H3, a new member of the B7 superfamily, plays a key role in the regulation of T cell-mediated immune responses.. Our previous work showed that B7-H3 strongly augmented both LPSand bacterial lipoprotein-induced NFκB activation and inflammatory response, and soluble B7H3 was elevated in CSF and plasma of patients with bacterial meningitis.. MMP-9 has been implicated in blood–brain barrier disruption, inflammation, and vasculitis during the pathogenesis of bacterial meningitis.

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Grouping and evaluation of clinical disease status Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..

    Control:

    Article Title: Effects of B7-H3 on the inflammatory response and expression of MMP-9 in mice with pneumococcal meningitis.
    Article Snippet: B7-H3, a new member of the B7 superfamily, plays a key role in the regulation of T cell-mediated immune responses.. Our previous work showed that B7-H3 strongly augmented both LPSand bacterial lipoprotein-induced NFκB activation and inflammatory response, and soluble B7H3 was elevated in CSF and plasma of patients with bacterial meningitis.. MMP-9 has been implicated in blood–brain barrier disruption, inflammation, and vasculitis during the pathogenesis of bacterial meningitis.

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Grouping and evaluation of clinical disease status Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..

    Saline:

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Grouping and evaluation of clinical disease status Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..

    Article Title: B7 homolog 3 aggravates brain injury in a murine model of Streptococcus pneumoniae -induced meningitis
    Article Snippet: .. Mice were randomized into one of the following four experimental groups, and each mouse received an intracerebroventricular injection of 15 μl in total: i) Control group, injected with 15 μl normal saline (NS); ii) B7-H3 group, injected with 15 μl NS containing 3.3 μg recombinant mouse B7-H3 (R&D Systems, Minneapolis, MN, USA); iii) SP group, injected with 15 μl NS containing 0.5×10 4 CFU/ml SP; and iv) SP plus B7-H3 group, injected with 5 μl NS containing 1.5×10 4 CFU/ml SP and 10 μl NS containing 3.3 μg B7-H3. ..



    Similar Products

    94
    Sino Biological biotinylated recombinant mouse b7h3
    Biotinylated Recombinant Mouse B7h3, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/Mouse+CD276+%2F+B7-H3+Protein+(His+Tag)%2C+Biotinylated/pm41826511-853-14-18
    Average 94 stars, based on 1 article reviews
    biotinylated recombinant mouse b7h3 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    92
    MedChemExpress recombinant mouse b7h3 protein
    Recombinant Mouse B7h3 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/CD276%2FB7-H3%2C+Mouse/pm41826511-901-0-4
    Average 92 stars, based on 1 article reviews
    recombinant mouse b7h3 protein - by Bioz Stars, 2026-10
    92/100 stars
      Buy from Supplier

    92
    R&D Systems b7h3
    Figure 1. Schematic representation of our hybrid-SELEX method for selection of <t>B7H3-specific</t> ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.
    B7h3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/Recombinant+Mouse+B7-H3+Protein/pm38866941-139-7-8
    Average 92 stars, based on 1 article reviews
    b7h3 - by Bioz Stars, 2026-10
    92/100 stars
      Buy from Supplier

    92
    R&D Systems recombinant mouse
    Figure 1. Schematic representation of our hybrid-SELEX method for selection of <t>B7H3-specific</t> ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.
    Recombinant Mouse, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/Recombinant+Mouse+B7-H3+Fc+Chimera+Protein%2C+CF/pmc11078193-242-0-6
    Average 92 stars, based on 1 article reviews
    recombinant mouse - by Bioz Stars, 2026-10
    92/100 stars
      Buy from Supplier

    94
    Sino Biological recombinant monkey b7 h3 protein
    Figure 1. Schematic representation of our hybrid-SELEX method for selection of <t>B7H3-specific</t> ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.
    Recombinant Monkey B7 H3 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/Mouse+B7-H3+%2F+CD276+Protein/us11891445-741-32-49
    Average 94 stars, based on 1 article reviews
    recombinant monkey b7 h3 protein - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Sino Biological recombinant mouse b7 h3 protein
    Figure 1. Schematic representation of our hybrid-SELEX method for selection of <t>B7H3-specific</t> ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.
    Recombinant Mouse B7 H3 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/Mouse+B7-H3+%2F+CD276+Protein/us11891445-741-8-25
    Average 94 stars, based on 1 article reviews
    recombinant mouse b7 h3 protein - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    92
    MedChemExpress recombinant b7 h3 fc 273 protein 274 non tissue culture
    Figure 1. Schematic representation of our hybrid-SELEX method for selection of <t>B7H3-specific</t> ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.
    Recombinant B7 H3 Fc 273 Protein 274 Non Tissue Culture, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/CD276%2FB7-H3%2C+Mouse/ppr0800504-125-8-35
    Average 92 stars, based on 1 article reviews
    recombinant b7 h3 fc 273 protein 274 non tissue culture - by Bioz Stars, 2026-10
    92/100 stars
      Buy from Supplier

    92
    R&D Systems Hematology murine b7 h3 antigen
    Figure 1. Schematic representation of our hybrid-SELEX method for selection of <t>B7H3-specific</t> ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.
    Murine B7 H3 Antigen, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/Recombinant+Mouse+B7-H3+Protein/us11680100-321-18-23
    Average 92 stars, based on 1 article reviews
    murine b7 h3 antigen - by Bioz Stars, 2026-10
    92/100 stars
      Buy from Supplier

    92
    R&D Systems Hematology murine b7 h3
    Figure 1. Schematic representation of our hybrid-SELEX method for selection of <t>B7H3-specific</t> ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.
    Murine B7 H3, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+b7+h3/Recombinant+Mouse+B7-H3+Protein/us11680100-286-13-15
    Average 92 stars, based on 1 article reviews
    murine b7 h3 - by Bioz Stars, 2026-10
    92/100 stars
      Buy from Supplier

    Image Search Results


    Figure 1. Schematic representation of our hybrid-SELEX method for selection of B7H3-specific ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.

    Journal: Scientific reports

    Article Title: Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays.

    doi: 10.1038/s41598-024-64559-7

    Figure Lengend Snippet: Figure 1. Schematic representation of our hybrid-SELEX method for selection of B7H3-specific ssDNA aptamer. (a) Retinoblastoma cell-SELEX to develop aptamers against retinoblastoma using Weri-RB1 cells and target cell and Mio-M1 as control cells. (b) We have screened the RB cell-SELEX enriched pools on recombinant B7H3 protein by dot-blot and chose the cell-SELEX enriched pool-15 (CSEP-15) as the starting library for the B7H3 hybrid SELEX. In our experiment, the hybrid-SELEX process is divided into (c) the B7H3 protein- based SELEX selection and (d) cell-based SELEX enrichment. The CSEP-15 is incubated with B7H3 protein immobilized on magnetic beads for positive selection and empty magnetic beads for counter selection for each cycle in protein-SELEX. The pool enriched from protein SELEX is incubated with Weri-RB1 for positive selection and Mio-M1 for counter selection in cell-SELEX. After 9 rounds of selection, the enriched aptamer pools were sequenced by NGS. SELEX, Systematic Evolution of Ligands by EXponential enrichment.

    Article Snippet: However, the recombinant protein manufacturer of the B7H3 (R&D systems) reported a molecular weight of 38–48 kDa for its product which is consistent with the strongly detected band’s weight (Full raw blot included in Supplementary data Fig. S5).

    Techniques: Selection, Control, Recombinant, Dot Blot, Incubation, Magnetic Beads

    Figure 2. Monitoring the enrichment of the DNA libraries during hybrid-SELEX by flow cytometry and dot- blot. (a) Fluorescence intensities of target cells (Weri-RB1) incubated with FITC-labelled ssDNA pools from the initial library to the ninth-selection round. (b) Fluorescence intensities of negative control cells (Mio-M1) incubated with FITC-labelled ssDNA pools from the initial library to the ninth-selection round. (c) Represented is the dot-blot assay showing the fluorescence intensities of ssDNA pools from the initial library to the ninth- selection round, bound to the recombinant B7H3 protein.

    Journal: Scientific reports

    Article Title: Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays.

    doi: 10.1038/s41598-024-64559-7

    Figure Lengend Snippet: Figure 2. Monitoring the enrichment of the DNA libraries during hybrid-SELEX by flow cytometry and dot- blot. (a) Fluorescence intensities of target cells (Weri-RB1) incubated with FITC-labelled ssDNA pools from the initial library to the ninth-selection round. (b) Fluorescence intensities of negative control cells (Mio-M1) incubated with FITC-labelled ssDNA pools from the initial library to the ninth-selection round. (c) Represented is the dot-blot assay showing the fluorescence intensities of ssDNA pools from the initial library to the ninth- selection round, bound to the recombinant B7H3 protein.

    Article Snippet: However, the recombinant protein manufacturer of the B7H3 (R&D systems) reported a molecular weight of 38–48 kDa for its product which is consistent with the strongly detected band’s weight (Full raw blot included in Supplementary data Fig. S5).

    Techniques: Flow Cytometry, Dot Blot, Fluorescence, Incubation, Selection, Negative Control, Recombinant

    Figure 3. Binding ability, secondary structures and dissociation constants of selected B7H3 aptamers. (a) Binding affinity of FITC-labelled aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 to Weri-RB1 cells assessed by flow cytometry. (b) Binding ability of FITC-labelled aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 to Mio-M1 cells assessed by flow cytometry. (c–g) Predicted secondary structures for five aptamer candidates, VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 selected for further. The presented predicted secondary structures were the ones with lowest ΔG. Constant sequence regions are highlighted in black, and green represents the random regions. (h–l) Binding curve of aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 with Weri-RB1 and Mio-M1 cells assessed by flow cytometry and recombinant B7H3 protein by dot-blot. Equilibrium dissociation constants (Kd) (nM) were calculated using GraphPad Prism 7, under the non-linear fit model, one-site non-competitive binding to fluorescent population ratio at used aptamer concentrations.

    Journal: Scientific reports

    Article Title: Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays.

    doi: 10.1038/s41598-024-64559-7

    Figure Lengend Snippet: Figure 3. Binding ability, secondary structures and dissociation constants of selected B7H3 aptamers. (a) Binding affinity of FITC-labelled aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 to Weri-RB1 cells assessed by flow cytometry. (b) Binding ability of FITC-labelled aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 to Mio-M1 cells assessed by flow cytometry. (c–g) Predicted secondary structures for five aptamer candidates, VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 selected for further. The presented predicted secondary structures were the ones with lowest ΔG. Constant sequence regions are highlighted in black, and green represents the random regions. (h–l) Binding curve of aptamers VRF-HS_B7H3-01, VRF-HS_B7H3-02, VRF-HS_B7H3-03, VRF-HS_B7H3-04 and VRF-HS_B7H3-05 with Weri-RB1 and Mio-M1 cells assessed by flow cytometry and recombinant B7H3 protein by dot-blot. Equilibrium dissociation constants (Kd) (nM) were calculated using GraphPad Prism 7, under the non-linear fit model, one-site non-competitive binding to fluorescent population ratio at used aptamer concentrations.

    Article Snippet: However, the recombinant protein manufacturer of the B7H3 (R&D systems) reported a molecular weight of 38–48 kDa for its product which is consistent with the strongly detected band’s weight (Full raw blot included in Supplementary data Fig. S5).

    Techniques: Binding Assay, Flow Cytometry, Sequencing, Recombinant, Dot Blot

    Figure 4. Affinity of B7H3 aptamers by Dot-blot and western blot analysis. (a) Dot-blot assay with (i–v) FITC labelled and (vi–x) biotin labelled aptamers to demonstrate the capability of the B7H3 aptamers to recognize their target immobilized on PVDF membranes; (i) & (vi)—VRF-HS_B7H3-01, (ii) & (vii)—VRF-HS_B7H3-02, (iii) & (viii)—VRF-HS_B7H3-03, (iv) & (viii)—VRF-HS_B7H3-04 and (v) & (x)—VRF-HS_B7H3-05; 1— B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate, 4—BSA, 5—Weri-RB1 secretome and 6—Secondary control. (b) Sandwich dot blot assay with (i–iii) biotin labelled and (ii–iv) FITC labelled aptamers to demonstrate the capability of aptamers to recognize different epitopes of their target immobilized on nitrocellulose membranes. (i) & (ii)—unlabelled VRF-HS_B7H3-01 is used as capture and FITC or biotin labelled VRF-HS_B7H3-03 is used for detection, (iii) & (iv) unlabelled VRF-HS_B7H3-03 is used as capture and FITC or biotin labelled VRF-HS_B7H3-01 is used for detection; 1—B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate, 4—Weri-RB1 secretome and 5—BSA. (c) Comparison of the specificity of B7H3 antibody to VRF-HS_B7H3-03 aptamer in a protein blot analysis (cropped image). Lane 1—B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate and 4—Mio-M1 protein lysate; (i) Probed with anti-B7H3 Rabbit monoclonal antibody, (ii) Probed with biotinylated VRF-HS_B7H3-03 aptamer and (iii) & (iv) Probed with GAPDH mouse monoclonal antibody. Results of an aptamer blot from a nonreducing SDS polyacrylamide gel in which B7H3 was clearly detected near 90 kDa similar to antibody. However, the recombinant protein manufacturer of the B7H3 (R&D systems) reported a molecular weight of 38–48 kDa for its product which is consistent with the strongly detected band’s weight (Full raw blot included in Supplementary data Fig. S5).

    Journal: Scientific reports

    Article Title: Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays.

    doi: 10.1038/s41598-024-64559-7

    Figure Lengend Snippet: Figure 4. Affinity of B7H3 aptamers by Dot-blot and western blot analysis. (a) Dot-blot assay with (i–v) FITC labelled and (vi–x) biotin labelled aptamers to demonstrate the capability of the B7H3 aptamers to recognize their target immobilized on PVDF membranes; (i) & (vi)—VRF-HS_B7H3-01, (ii) & (vii)—VRF-HS_B7H3-02, (iii) & (viii)—VRF-HS_B7H3-03, (iv) & (viii)—VRF-HS_B7H3-04 and (v) & (x)—VRF-HS_B7H3-05; 1— B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate, 4—BSA, 5—Weri-RB1 secretome and 6—Secondary control. (b) Sandwich dot blot assay with (i–iii) biotin labelled and (ii–iv) FITC labelled aptamers to demonstrate the capability of aptamers to recognize different epitopes of their target immobilized on nitrocellulose membranes. (i) & (ii)—unlabelled VRF-HS_B7H3-01 is used as capture and FITC or biotin labelled VRF-HS_B7H3-03 is used for detection, (iii) & (iv) unlabelled VRF-HS_B7H3-03 is used as capture and FITC or biotin labelled VRF-HS_B7H3-01 is used for detection; 1—B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate, 4—Weri-RB1 secretome and 5—BSA. (c) Comparison of the specificity of B7H3 antibody to VRF-HS_B7H3-03 aptamer in a protein blot analysis (cropped image). Lane 1—B7H3 Recombinant protein, 2—RB tumor protein lysate, 3—Weri-RB1 protein lysate and 4—Mio-M1 protein lysate; (i) Probed with anti-B7H3 Rabbit monoclonal antibody, (ii) Probed with biotinylated VRF-HS_B7H3-03 aptamer and (iii) & (iv) Probed with GAPDH mouse monoclonal antibody. Results of an aptamer blot from a nonreducing SDS polyacrylamide gel in which B7H3 was clearly detected near 90 kDa similar to antibody. However, the recombinant protein manufacturer of the B7H3 (R&D systems) reported a molecular weight of 38–48 kDa for its product which is consistent with the strongly detected band’s weight (Full raw blot included in Supplementary data Fig. S5).

    Article Snippet: However, the recombinant protein manufacturer of the B7H3 (R&D systems) reported a molecular weight of 38–48 kDa for its product which is consistent with the strongly detected band’s weight (Full raw blot included in Supplementary data Fig. S5).

    Techniques: Dot Blot, Western Blot, Recombinant, Control, Comparison, Molecular Weight

    Figure 5. Immunohistochemistry of B7H3 antibody and VRF-HS_B7H3-03 to RB tumour sections and retina. (a,d) H and E staining, (b,e) IHC with B7H3 antibody, and (c,f) IHC with biotin-labelled VRF-HS_B7H3-03 of primary retinoblastoma tumour and retina respectively.

    Journal: Scientific reports

    Article Title: Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays.

    doi: 10.1038/s41598-024-64559-7

    Figure Lengend Snippet: Figure 5. Immunohistochemistry of B7H3 antibody and VRF-HS_B7H3-03 to RB tumour sections and retina. (a,d) H and E staining, (b,e) IHC with B7H3 antibody, and (c,f) IHC with biotin-labelled VRF-HS_B7H3-03 of primary retinoblastoma tumour and retina respectively.

    Article Snippet: However, the recombinant protein manufacturer of the B7H3 (R&D systems) reported a molecular weight of 38–48 kDa for its product which is consistent with the strongly detected band’s weight (Full raw blot included in Supplementary data Fig. S5).

    Techniques: Immunohistochemistry, Staining